Equip Rotavirus

10 x 1 dose

Emulsion for Injection

Active substance

Rota virus (strain H2) (serotype G3 P12) (attenuated)

ATC code

QI05AA09 Equine rotavirus

QI05AA Inactivated viral vaccines

QI05A Immunologicals for horse

QI05 Immunologicals for equidae

QI Immunologicals

Species

Horses (pregnant mares).

Indications

For vaccination of pregnant mares to provide passive transfer of antibodies to foals to reduce the risk of diarrhoea caused by equine rotavirus type G3P12.

Mares are able to transfer the passive immunity to the foals 4 weeks after the third vaccination. Foals of the vaccinated mares show an increase in antibodies against equine rotavirus for approximately sixty days.

Dose to be administered and administration route

Intramuscular use.

1 ml dose per mare to be administered by deep intramuscular injection.

Vaccination schedule:

Pregnant mares should be given three doses of vaccine consisting of a single 1 ml dose administered at the 8th, 9th and 10th month of each pregnancy.

Adverse reactions

Horses (pregnant mares):

Very common

(>1 animal / 10 animals treated):

Elevated temperature^{^[1]}

Common

(1 to 10 animals / 100 animals treated):

Injection site pain^{^[2]}, Injection site swelling³

¹A transient increase (up to 1.8 °C) in rectal temperature which may last up to 2 days.

²At the swelling site. May last 1-2 days.

³A small visible soft to firm swelling (2.5 ≤ x ≤ 3.5 cm) lasting generally for only 2 days. In most cases these small and transient injection site reactions resolve with no need for treatment.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.